✦ LIBER ✦

PHNO, a novel dopamine agonist, in animal models of parkinsonism

✍ Scribed by Dr. William Koller; Gregory Herbster; John Gordon

Publisher: John Wiley and Sons
Year: 1987
Tongue: English
Weight: 347 KB
Volume: 2
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.870020306

No coin nor oath required. For personal study only.

✦ Synopsis

PHNO, a naphthoxazine compound, was investigated in animal models of central dopaminergic activity. The drug in doses of 5-300 micrograms/kg when administered subcutaneously, or transdermally, induced stereotypic behavior in rats which was blocked by haloperidol but not by reserpine pretreatment. In rats with unilateral 6-hydroxydopamine lesions of the substantia nigra PHNO induced dose-dependent contralateral turnings. The drug caused emesis in dogs and hypothermia in mice. PHNO bound to D-2 dopamine receptors in the rat striatum. Chronic injection with PHNO did not induce behavioral supersensitivity or increase dopamine receptor density. These data indicate that PHNO is a direct acting dopamine agonist that is highly potent. PHNO differs from other dopaminergic drugs and may be useful in the treatment of Parkinson's disease.

📜 SIMILAR VOLUMES

N-0923, A novel soluble dopamine D2 agon

N-0923, A novel soluble dopamine D2 agonist in the treatment of parkinsonism

✍ Vincent P. Calabrese; K. Alvin Lloyd; Pasquale Brancazio; Eugene Cefali; Pauline 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 614 KB

N-0923, a novel aminotetralin dopamine D2 agonist, was shown to effectively reverse parkinsonian symptoms in nine dopa/agonist-responsive Parkinson's disease patients. The drug was given up to 4.5 hours by continuous intravenous (i.v.) infusion using an i.v. pump. The onset of anti-parkinsonian effe

Continous intracerebroventricular infusi

Continous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease

✍ Dr. J. G. De Yebenes; S. Fahn; S. Lovelle; V. Jackson-Lewis; P. Jorge; M. A. Men 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 831 KB

We studied the effect of intracerebroventricular infusion of dopamine and dopamine agonists in rat and primate models of Parkinson's disease as an experimental approach to the treatment of levodopa-induced fluctuations. The infusion of dopamine, lisuride, and pergolide into the ventricle ipsilateral

Dopamine receptor agonists reverse behav

Dopamine receptor agonists reverse behavioral abnormalities of α-synuclein transgenic mouse, a new model of Parkinson's disease

✍ Masaki Wakamatsu; Shingo Iwata; Takeo Funakoshi; Makoto Yoshimoto 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 272 KB

## Abstract Parkinson's disease (PD) is characterized by loss of nigral dopaminergic (DAergic) neurons and presence of Lewy bodies, whose major component is α‐synuclein. We had previously generated transgenic mice termed __Syn130m__ that express truncated human α‐synuclein (amino acid residues 1–13

Double-blind study of pardoprunox, a new

Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease

✍ Juliana Bronzova; Cristina Sampaio; Robert A. Hauser; Anthony E. Lang; Olivier R 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 1 views

## Abstract This study examined the efficacy and safety of the partial dopamine agonist, pardoprunox (SLV308), in the treatment of patients with early Parkinson's disease (PD). Patients were randomized to receive pardoprunox (n = 69) or placebo (n = 70). Pardoprunox was titrated to each patient's o

N-0923, a selective dopamine D2 receptor

N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease

✍ Dr. J. D. Belluzzi; E. F. Domino; J. M. May; K. S. Bankiewicz; D. A. McAfee 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 800 KB

## Abstract Certain aminotetralins are known to be potent dopamine D~2~ receptor agonists. N‐0923, [‐]2‐(N‐propyl‐N‐2‐thienylethylamino)‐5‐hydroxytetralin HCl, recognizes the high and low affinity states of the D~2~ receptor in membranes from bovine caudate with a K~low~ of 79 nM. The selectivity r

Long-term tolerability and efficacy of c

Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease

✍ R. Inzelberg; P. Nisipeanu; M. J. Rabey; Prof. A. D. Korczyn 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 333 KB 👁 2 views

## Abstract Motor fluctuations constitute a severe complication of chronic levodopa therapy. The addition of dopamine agonists may partially alleviate these responses; however, due to the short half‐lefe of these drugs, several daily doses are required. Cabergoline is a new dopamine agonist with a